OrganiGram Short Interest Ratio and Short Volume

Short interest is the volume of OrganiGram shares that have been sold short but have not yet been closed out or covered. As of January 29th, investors have sold 8,350,000 shares of OGI short. 3.62% of OrganiGram's shares are currently sold short. View details.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.62% of OrganiGram's floating shares are currently sold short.

OrganiGram saw a decline in short interest in January. As of January 29th, there was short interest totaling 8,350,000 shares, a decline of 8.3% from the previous total of 9,110,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

OrganiGram currently has issued a total of 232,109,000 shares. Some of OrganiGram's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OrganiGram currently has a public float of 230,950,000 shares.

3.62% of OrganiGram's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to OrganiGram: Amicus Therapeutics, Inc. (0.00%), Corcept Therapeutics Incorporated (10.87%), Rocket Pharmaceuticals, Inc. (0.00%), OPKO Health, Inc. (25.34%), Global Blood Therapeutics, Inc. (0.00%), Intra-Cellular Therapies, Inc. (0.00%), Prelude Therapeutics Incorporated (3.47%), IGM Biosciences, Inc. (15.83%), Viela Bio, Inc. (12.59%), and CytoDyn Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling OGI is an investing strategy that aims to generate trading profit from OrganiGram as its price is falling. OrganiGram's stock is trading up $0.32 today. To short OrganiGram stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that OrganiGram will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for OrganiGram occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OGI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OGI, twice per month. The most recent reporting period available is January, 29 2021.